Penetrance of Methylene Tetrahydrofolate Reductase C677T Gene Polymorphism and Karyotypic Variations Associated Increase Genetic Susceptibility in the Cases of Congenital Heart Defects

MTHFR-cr,5’- CCATGTCGGTGCATGCCTTCACAAAG-3’.

To obtain amplicons with distinct melting points, ‘Tm’ values were calculated using known software (http://eu.idtdna.com/ analyzer/Applications/OligoAnalyzer/). We have plan to select these primer ARMS PCR based on “Tm” analysis, part of plan of our interest to detect SNP of mutant of MTHFR allele(s), same PCR product was further confirmed by agarose gel (2.0%) electrophoresis and bands were visualized and characterized after ethidium bromide staining on Gel Doc system.

Simple procedure includes a total volume of 20 μl containing 10 μl of SYBR Green PCR Master Mix, 1 μl of each primer per reaction, 40 ng of genomic DNA, and distilled water was taken to perform RT-PCR. The PCR protocol on the light cycler included an initial denaturation step (95 0C for 7 min) was followed by amplification and quantification steps repeated for 30–40 cycles (950C for 10 s, 600C for 10 s, 720C for 20 s), with a single fluorescence measurement at the end of the elongation step at 720C, reaction was terminated by cooling to 400C. Melting curves were constructed by lowering the temperature to 650C and later increasing the temperature by 0.20C/s to 980C to measuring the change in fluorescence consistently. Tm values were assigned to develop plot generated by the RT-PCR of the negative derivation of fluorescence versus temperature (dF/ dT) of the melting curve for amplification products measured at 530 nm.

Statistical Analysis

Chi square (X2) test was used to find to calculate p value and level of significance (p=value) between normal and abnormal cells during analysis of karyotypes in individual case of CHDs.

Results

Cytogenetics analysis in CHD cases were performed for developing karyotypes individual to find end point according to ISCN 2016. The cytogenetic findings include a spectrum of GTG karyotypes showing large number of structural and numerical variations in individual cases of CHDs with brief history. The detail findings of numerical as well as structural variations (% frequency) in individual cases were documented in Table 1.

Case-I

Three months old male child, clinically diagnosed CHD based on findings of ECHO cardiogram with AV+VA concordance and RA/ RV mildly enlarged. The cytogenetic study showing dominantly of 47 XY+21, confirmed down syndrome with the frequency of 58.3%. Other trisomy identified were 47 XY +20 karyotype (4.16%), 47 XY+18 (4.16%), 47 XY +22 (4.16%), 47 XY +9 (4.16%), 47 XY+8 (4.16%), 47XY+11 4.16%); 45 XY -11 (4.16%).

Case-II

The one and half month-old, female child presented with CHD with clinical features including abnormal echocardiogram showing VSD (having thickness of 0.5 cm) with clinical features of Down’s syndrome The frequency of numerical variations having trisomy - 21 (47 XX+21) were 50% and 47 XX+11 was 12.5%.

Case-III

This case includes male, age two year and one month have AV malformations with multiple venous malformations in chest and abdominal wall with significant fatty components and diffusely infiltrated muscles (angiography). Karyotypes shows 15% of cells with trisomy - 21 (47 XY+21) while trisomy -12 (47 XY+12) is 7.7%. In this case the structural chromosomal abnormities are dominant and shows more than 30%, such as chromatid breaks of chromosome - 2 (2p) and chromosome 10 (10q) and formation of ring of Y chromosome. Besides these structural abnormalities one metaphase showed centromere breakage (> 60%) in chromosomes.

Case-IV

(P-593), Clinically diagnose on the bases of echocardiogram showing Situs Solitus, AV/VA concordance, Chamber size normal, valves normal. Cytogenetics findings includes 47 XY +18 (25%); 47XY+14 (8.3%), 45 XY-11 (8.3 %) and 45XY -17 (8.3%). Structural aberrations showing more than 8% chromatid breaks involving chromosome 1(1p23).

The variations in the frequency of chromosomes due to different clinical conditions and severity of disease. Interestingly, numerical variations and their frequency are predominantly dominated in all the cases of CHD including in the karyotypes of trisomy-21, 18, and monosomy of chromosome -11, a representative karyotype showing trisomy-21 is shown (Figure 1A). Simultaneously, structural chromosomal aberrations including chromatid breaks in chromosome -1(-1q) and 2 (-2p), besides this formation of Y-ring chromosome and centromeric breakage were the striking feature in two cases of CHD with frequency > 8% to 30%, respectively. The numerical chromosomal variations were observed in all the four cases with maximum frequency (58.30%) were observed in karyotypes 47, XY + trisomy 21. The extra copy of chromosome-21 was further confirmed by FISH analysis using specific probe LSI 21 spectrum orange having region 21q22.13-q22.2 of 220 kb as shown in Figure 1B. Interestingly, only one case showing lack of trisomy - 21, but extra copy of chromosome -18, 14 (trisomy) was observe with monosomy of chromosome -11, 17, respectively.

Single nucleotide polymorphism (SNP) of MTHFR gene regulate folate metabolism is important event during embryogenesis. Highly sensitive, allele refractive mutation specific (ARMS) PCR based technique is used for SNP analysis to determine “risk factor” of MTHFR C677T genotyping - wild-type (CC) allele and mutant (TT) allele in homozygous condition and heterozygous condition (CT). In all the cases of CHDs, the Tm value showing shift from 82.50C to 83.00C, suggesting increase heterozygocity (CT) in 25% of cases due to allele C change into T (C→ T) as mentioned in Figure 2A, suggesting increase “risk” of the disease, while rest of the three cases (75%) showing only wild type of genotype CC (Figure 2A- 2C). The findings RT-PCR were further confirmed the appearance of additional band of 105 kb belong to mutant “T” allele (Case - 3) on agarose gel electrophoresis as documented in Figure 2C.

Discussion

The etiopathology of CHDs are complex due to the interactions of genetic and environmental factors [4,22]. It has been identified that ~30% of CHD cases are syndromic involving chromosomal aberrations, while non-syndromic are monogenic and shows variety of genes. Now it is evident form preview of the fact that genetic factors become essential to understand the etiopathology in CHD cases and risk assessment before initiation of clinical management and counselling. However, there is lack of the genetic knowledge of CHDs in Indian population, only few studies have been achieved to study an association of genetic factors in CHDs. Therefore, present study was performed to accumulate the data from different approaches like karyotypic pattern and MTHFR (C677T) gene polymorphism to determine “risk factors” in CHD patients.

Epidemiological studies revel that frequency (%) and types of chromosomal abnormalities varies between USA or Europe, but there is a lack of data in Indian population. Hence, the present study on CHDs becomes relevant to assess the risk using MTHFR C677T gene polymorphism analysis and try to correlate with karyotypic variations with agreement by the authors present study is small, but quite interesting. Previous studies identified chromosomal abnormalities with variation in the frequency from 3-18% in CHDs due to different variables such as clinical characteristics, age and ethnicity [22, 23]. In the present study, numerical variations (trisomy-21) show very high frequency (58.30%) and dominant over all kind of structural and numerical variations, the detail data of cytogenetics is documented in tabular form (table-I). Present findings are the agreement of earlier studies that trisomy-21 and 18 are associated with the cases of CHD [23,24]. Previous stud also reported trisomy-13, however, such chromosomal aberrations failed to observe in the present study may be either due to small sample size or different environmental factors [24].

In the present study, frequency of structural chromosomes was varying from 8-30% alone over total cytogenetics alterations and more interesting than numerical end point due to the appearance of “Y-ring chromosome and centromeric breakage reporting first time. Author failed to interpret the present findings that there might be involvement of conserve DNA sequences exist at centromeric regions and role of sex-chromosome during pathogenesis of CHD cases. Earlier study shows the deletion of the short arm of chromosome - 6 and 17, while present study also documented chromatid breaks - unstable regions of chromosomes [22-25]. Interestingly, present study shows “novel” structural changes has not been reported earlier with high impact on genomic instability of CHDs genome.

The conversion of folate 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate in multistep processes that converts homocysteine to S-adenosyl methionine involving methyl donor for the maintenance of several biological processes. Methionine is incorporated into protein synthesis, growth and metabolism processes. The S-adenosyl methionine serves as a role for clearance of harmful substances, metabolites and waste products more efficiently. Earlier study shows that deficiency in MTHFR activity leads to increase homocysteine and lowering of folate levels in circulation. Homocysteine, is a Sulphur containing amino acid, acts as biomarker of “risk factor” of cardiovascular disease by promoting oxidation of lipids and lipoproteins [26]. Growing number of evidence also suggest that mutations in folate metabolism may also be involved in genetic susceptibility to CHD. In 2001, Junker and colleagues showed that significant association of MTHFR 677TT genotype in the development of CHDs during early pregnancy [8-11, 27]. There is still needed to explore new variants of MTHFR and their association to the “risk factor” during organogenesis in developing countries like India needs to be explored. In the present study, we report for the first time the role of MTHFR C677T polymorphism and codominance of chromosome variations in CHDs cases in the Eastern region of India. Previously, few studies have been reported mutant “T’’ allele of MTHFR in CHDs [18,19]. Our results indicate that the frequency of the putative risk allele C677T was 25%, which is similar to meta-analysis study performed by Xuan et al where they identified frequency of 28.99% in Caucasian children and 31.76% in the Caucasian maternal population, although higher frequency (42.28%) has been reported in Asian population [28]. Importantly, studies by Hobbs and co-workers identified Hcy, S-adenosylhomocysteine, and methionine as the most important biomarkers predictive in mothers whose pregnancies were affected by congenital heart defects (224 case subjects) or unaffected by any birth defect (90 control subjects)7. The variations in allele frequency may be either due to different clinical feature or penetrance of mutant allele to the CHDs genome to increase severity of the disease, but simultaneously the epigenetic factors should not be ignored.

Conclusion

From the present study we are reporting first time the penetrance of MTHFR C677T gene polymorphism as “risk factor” with karyotypic variations in the cases of CHDs. Although, this study is based on small group, but findings are promising with new findings in chromosome aberrations are documented as independent risk factor during embryogenesis, suggesting to increase large samples size for validity of the findings in other groups. However, other than genetic factor influences by consanguinity and environmental factors (socioeconomic) together cause genomic instability resulting abnormal development of foetus such as CHDs.

Acknowledgement

AKS thankfully acknowledges to the Director, AIIMS Patna also give special thanks to the patients who participates in the study.

Conflict of Interest

All the authors have agreed with the content of the manuscript. There is no conflict of interest between the authors.

Authors Contributions

AKS and MT are involved for genetics analysis, SK is responsible for clinical diagnosis and management of the patients, while CK help during preparation of the manuscript.

References

1. Mary Ella Pierpont, Craig T Basson, D Woodrow Benson Jr, Bruce D Gelb, Therese M Giglia, et al. (2007) Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 115(23): 3015-3038.
2. Richards AA, Garg V (2010) Genetics of congenital heart disease. Curr Cardiol Rev 6(2): 91-97.
3. Chaix MA, Andelfinger G, Khairy P (2016) Genetic testing in congenital heart disease: A clinical approach. World J Cardiol 8(2): 180-191.
4. Tian G, Gao H, Hu S, Shu Q (2018) Research progress on genetic and epigenetic mechanisms in congenital heart disease. Zhejiang Da Xue Xue Bao Yi Xue Ban 47(3): 227-238.
5. Benhaourech S, Drighil A, Hammiri AE (2016) congenital heart disease and Down syndrome: various aspects of a confirmed association. Cardiovasc J Afr 27(5): 287-290.
6. Zhu WL, Li Y, Yan L, Dao J, Li S (2006) Maternal and offspring MTHFR gene C677T polymorphism as predictors of congenital atrial septal defect and patent ductus arteriosus. Mol Hum Reprod 12(1): 51-54.
7. Charlotte A Hobbs, Mario A Cleves, Stepan Melnyk, Weizhi Zhao, S Jill James (2005) Congenital heart defects and abnormal maternal biomarkers of methionine and homocysteine metabolism. Am J Clin Nutr 81(1): 147-153.
8. Chrysovalanto Mamasoula, R Reid Prentice, Tomasz Pierscionek, Faith Pangilinan, James L Mills, et al. (2013) Association between C677T polymorphism of methylene tetrahydrofolate reductase and congenital heart disease: meta-analysis of 7697 cases and 13,125 controls. Circ Cardiovasc Genet 6(4): 347-353.
9. Wang W, Wang Y, Gong F, Zhu W, Fu S (2013) MTHFR C677T polymorphism and risk of congenital heart defects: evidence from 29 case-control and TDT studies. PLoS One 8(3): e58041.
10. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M (2017) Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 8(8): CD006612.
11. Zhang R,Huo C, Wang X,Dang B, Mu Y, et al. (2018) Two Common MTHFR Gene Polymorphisms (C677T and A1298C) and Fetal Congenital Heart Disease Risk: An Updated Meta-Analysis with Trial Sequential Analysis. Cell Physiol Biochem 45(6): 2483-2496.  
12. Saxena Ajit K (2011) MTHFR C677T gene mutation associated with severe risk for mental retardation in children. Int J of Genetics 3(2): 47-49.
13. Gupta G, Gupta J, Pandey S, Pandey LK, Saxena Ajit K (2011) Role of Cell free fetal DNA in maternal blood - a prospective role of CβS & MTHFR gene as antenatal genetic marker in pre-eclampsia patients. Int. J. of Genet 3(2): 62-65.
14. Saxena Ajit K, Pandey S, Pandey LK (2012) Evaluation of Methylenetetrahydrofolate reductase C677T gene polymorphism associated risk factor in the patients of recurrent pregnancy loss. J. Med. Genet. Genomics 4(2): 25-28.
15. Singh A, Pandey S, Pandey LK, Saxena Ajit K (2015) In Human allele specific variation of MTHFR C677T and A1298C associate risk factor for the Development of Ovarian Cancer. J. Exp. Therap. Oncol 11(I): 67-70.
16. Saxena Ajit K, Tiwari M, Kumar V, Singh CK (2020) MTHFR New Gene Variants Increase Risk Factor in Wilms’ tumor and Prediction of 3D Structure Modulates Functional Activity During Drug-Protein Interaction. J of Integrative Oncol 10: 1.
17. Saxena Ajit K, Agarwal M, Kumar A, Singh CK (2021) Genetic heterogenecity of MTHFR C677T allele modulate hormonal dysfunction associated risk factors in the cases of male infertility. Int J Dev Res 12: 1-6.
18. Mukherjee M, Joshi S, Bagadi S, Dalvi M, Rao A, et al. (2002) A low prevalence of the C677T mutation in the methylenetetrahydrofolate reductase gene in Asian Indians. Clin Genet 61(2): 155-159.
19. Vasisht S, Gulati R, Narang R, N Srivastava,Lalit Mohan Srivastava, et al. (2002) Polymorphism (C677T) in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene: A preliminary study on north Indian men. Indian J Clin Biochem 17(1): 99-107.
20. Shaffer, Lisa G, Schmid M, McGowan-Jordan (2016) Iscn: An International System for Human Cytogenomic Nomenclature (2016). Basel: Karger.
21. Saxena Ajit K, Gupta RK, Kumar M (2016) ARMS-PCR based SNP analysis of MTHFR C677T allele using Syber green in pancreatic tumor. British Journal of Medicine and Medical Research 11(12): 1-6.
22. Robert J Hartman, Sonja A Rasmussen, Lorenzo D Botto, Tiffany Riehle-Colarusso, Christa L Martin, et al. (2011) The contribution of chromosomal abnormalities to congenital heart defects: a population-based study. Pediatr Cardiol 32(8): 1147-1157.
23. Patrícia Trevisan,1 Tatiana Diehl Zen, Rafael Fabiano Machado Rosa,Juliane Nascimento da Silva,Dayane Bohn Koshiyama, et al. (2013) Chromosomal abnormalities in patients with congenital heart disease. Arq Bras Cardiol 101(6): 495-501.
24. C Ferencz, C A Neill, J A Boughman, J D Rubin, J I Brenner, L W Perry (1989) Congenital cardiovascular malformations associated with chromosome abnormalities: an epidemiologic study. J Pediatr 114(1): 79-86.
25. Paskulin GA, Zen PR, Rosa RF, Manique RC, Cotter PD (2007) Report of a child with a complete de novo 17p duplication localized to the terminal region of the long arm of chromosome 17. Am J Med Genet A 143A (12): 1366-1370.
26. P Frosst, H J Blom, R Milos, P Goyette, C A Sheppard, et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1): 111-113.
27. R Junker, S Kotthoff, H Vielhaber, S Halimeh, A Kosch, et al. (2001) Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease. Cardiovasc Res 51(2): 251-254.
28. Chao Xuan, Hui Li, Jin-Xia Zhao, Hong-Wei Wang, Yi Wang, et al. (2014) Association between MTHFR polymorphisms and congenital heart disease: a meta-analysis based on 9,329 cases and 15,076 controls. Sci Rep 4: 7311.